3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Rituximab
10
Valganciclovir
6
Etoposide
4
Doxorubicin
4
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cyclophosphamide
3
Cisplatin
3
spartalizumab
2
pembrolizumab
2
pegaspargase
2
Zidovudine
2
Vincristine
2
Radiotherapy, Intensity-Modulated
2
Prednisone
2
Methylprednisolone
2
Methotrexate
2
Matrix-M
2
Leucovorin
2
Lenalidomide
2
Cell Count
2
Carboplatin
2
Blood Specimen Collection
2
Acyclovir
2
valomaciclovir
1
toripalimab
1
threonic acid
1
ruxolitinib
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Epstein-Barr Virus Infections
×
Darunavir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn